Ocular hypertension and glaucoma: The contribution of large studies to daily practice;Hypertonie oculaire et glaucome à angle ouvert: L'apport des grandes études cliniques dans la pratique quotidienne

Journal Francais d'Ophtalmologie

Volumn 25, Issue 6, 2002, Pages 641-654

  Bron, Alain ^a  

^a HÔPITAL DU BOCAGE   (France)

Author keywords

AGIS; CIGTS; CNTGS; EMGT; Glaucoma; Ocular hypertension; OHTS

Indexed keywords

ANTIGLAUCOMA AGENT;

CLINICAL PRACTICE; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG SAFETY; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MEDICAL PRACTICE; OPHTHALMOLOGY; PRACTICE GUIDELINE; REVIEW; TREATMENT PLANNING; VISUAL FIELD;

CLINICAL TRIALS; FAMILY PRACTICE; GLAUCOMA, OPEN-ANGLE; HUMANS; OCULAR HYPERTENSION; QUALITY ASSURANCE, HEALTH CARE;

EID: 0036073432     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. World health problem of glaucoma
2. Number of people with glaucoma worldwide
3. Randomized clinical trials on medical treatment of glaucoma. Are they appropriate to guide clinical practice?
4. A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects
5. Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals
6. A comparison of treated and untreated glaucoma suspects
7. Long term effect of timolol therapy in ocular hypertension: A double-masked randomised trial
8. Lack of long term drift in timolol's effectiveness in patients with ocular hypertension
9. Serial administration of adrenergic antagonist and agonist (pulsatile therapy) reduces the incidence of long-term drift to timolol in humans
10. The Ocular Hypertension Treatment Study: Design and baseline description of the participants
11. Baseline visual field characteristics in the ocular hypertension treatment study
12. Variability of static visual threshold responses in patients with elevated IOPs
13. Normal variability of static perimetric threshold values across the central visual field
14. Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study
15. The Ocular Hypertension Treatment Study: Reproducibility of cup/disk ratio measurements over time at an optic disc reading center
16. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS)
17. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975
18. Ocular hypertension. A prospective twenty-year follow-up study
19. The management of elevated intraocular pressure with normal optic discs and visual fields. I. Therapeutic approach based on high risk factors
20. Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons
21. Discriminating between normal and glaucomatous eyes using the Heidelberg Retina Tomograph, GDx Nerve Fiber Analyzer, and Optical Coherence Tomograph
22. Long-term functional outcome after early surgery compared with laser and medicine in POAG
23. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures
24. The treatment of normaltension glaucoma
25. Errors in the diagnosis of visual field progression in normaltension glaucoma
26. Intraocular pressure reduction in normal-tension glaucoma patients
27. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma
28. L'intention de traitement
29. Risk factors for progression of visual field abnormalities in normal-tension glaucoma
30. Natural history of normaltension glaucoma
31. Effect of surgery on visual field progression in normal tension glaucoma
32. Biostatistical evidence for two distinct chronic open angle glaucoma populations
33. The not quite natural history of normal-tension glaucoma
34. The use of visual field indices in detecting changes in the visual field in glaucoma
35. Rate of visual field loss and long-term visual outcome in primary open-angle glaucoma
36. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients
37. Advanced Glaucoma Intervention Study. 2. Visual field test scoring and reliability
38. The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients
39. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results
40. The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy
41. The advanced glaucoma intervention study, 6: Effect of cataract on visual field and visual acuity
42. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration
43. The advanced glaucoma intervention study, 8: Risk of cataract formation after trabeculectomy
44. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups
45. The Advanced Glaucoma Intervention Study (AGIS): 10. Variability among academic glaucoma subspecialists in assessing optic disc notching
46. Reliability of visual fields in AGIS
47. The development of encapsulated filtering blebs
48. Relationship between intraocular pressure and primary open angle glaucoma among white and black americans. The Baltimore eye survey
49. Risk factors for open-angle glaucoma. The Barbados Eye Study
50. The Collaborative Initial Glaucoma Treatment Study: Study design, methods, and baseline characteristics of enrolled patients
51. Scoring systems for measuring progression of visual field loss in clinical trials of glaucoma treatment
52. Quality of life in newly diagnosed glaucoma patients: The Collaborative Initial Glaucoma Treatment Study
53. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery
54. Correlation of visual field with quality-oflife measures at diagnosis in the Collaborative Initial Glaucoma Treatment Study (CIGTS)
55. The Collaborative Initial Glaucoma Treatment Study: Interim quality of life findings after initial medical or surgical treatment of glaucoma
56. Medical versus surgical therapy in early glaucoma
57. The Early Manifest glaucoma Trial Group: Early Manifest Glaucoma Trial, design and baseline data
58. Idendification of progressive glaucomatous visula field loss
59. Sources of error with use of Goldmann-type tonometers
60. La mesure de l'épaisseur cornéenne est-elle fiable et utile?
61. The enigma of POAG
62. Visual field prognosis in advanced glaucoma
63. The benefit of early trabeculectomy vs conventional management in POAG relative to the severity of the disease
64. Correlation between IOP control and progressive glaucomatous damage in POAG
65. The rate of visual field loss in untreated POAG
66. Treatment of glaucoma by lowering IOP
67. Risk factors for the development of glaucomatous visual field loss in ocular hypertension
68. Rate of progression in open-angle glaucoma estimated from cross-sectional prevalence of visual field damage
69. Glaucoma: The damage cause by pressure
70. Visual field progression in patients with initially unilateral visual field loss from chronic open-angle glaucoma
71. Clinical factors influencing the visual prognosis of the fellow eyes of normal tension glaucoma patients with unilateral field loss
72. The use of antimetabolites with trabeculectomy: A critical appraisal
73. Target pressure in glaucoma therapy
74. Surgical vs medical management of chronic open-angle glaucoma
75. Primary surgery for POAG, justified or not
76. Methodological variations in estimating apparent progressive visual field loss in clinical trials of glaucoma treatment
77. Long-term follow-up of initially successful trabeculectomy
78. The myth of 21